Transforming growth factor-beta and bone morphogenetic protein receptors (TGFBR/BMPR)

The Transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) receptors constitute a superfamily of transmembrane serine/threonine kinase receptors essential for regulating diverse cellular processes, including growth, differentiation, and apoptosis [2, 5]. These receptors function as heterotetrameric complexes composed of type I and type II subunits that, upon ligand binding, initiate intracellular signaling primarily through the canonical SMAD pathway [4, 11]. TGF-β signaling typically activates SMAD2 and SMAD3, while BMP signaling activates SMAD1, SMAD5, and SMAD8, both of which modulate gene transcription in the nucleus [9, 13]. Beyond development and homeostasis, dysregulation of these receptors is a hallmark of various diseases, such as organ fibrosis, cardiovascular disorders like pulmonary arterial hypertension, and cancer, where they can act as both tumor suppressors and promoters [8, 10, 16]. Therapeutic interventions targeting this system include small molecule inhibitors of the kinase domains, monoclonal antibodies against ligands or receptors, and ligand traps that sequester signaling molecules [7, 20, 21]. However, the broad biological impact of these pathways necessitates careful management of safety concerns, such as potential cardiotoxicity and the development of secondary skin lesions [7, 25].

Other names

TGF-beta receptorsBMP receptorsActivin receptorsALK receptorsSerine/threonine kinase receptorsTGF-beta superfamily receptorsTransforming growth factor-beta superfamily receptors

Inhibition of receptor serine/threonine kinase activity, sequestration of ligands using decoy receptors or antibodies, and competitive inhibition of ATP binding to the kinase domain [7, 20, 25].